The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.
age ≥ 50 years.
confirmed diagnosis of AMD in at least one eye.
follow-up scheduled according to standard clinical practice.
presence of other significant ocular conditions that could affect visual acuity.
systemic conditions that make the patient unsuitable for long-term follow-up.
Patients affected by age-related macular degeneration
Cohort
Other
Not listed
Best-corrected visual acuity (BCVA)
visual acuity measured as ETDRS letters
Self-reported vision-targeted quality of life
Self-reported vision-targeted quality of life will be measured using National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25). \[Score 0-100, higher scores mean a better outcome\]
Fluid volume (nL) in the retinal compartments
Artificial intelligence based fluid analysis. Measurement of fluid volume (nL) in the intraretinal, subretinal and sub retinal pigment epithelium compartments
central retinal thickness
central retinal thickness
Click on the lead sponsor to view all of their trials.
